Preprint
Review

Lung Cancer: Targeted Therapy in 2025

This version is not peer-reviewed.

Submitted:

03 February 2025

Posted:

04 February 2025

You are already at the latest version

Abstract
Lung cancer treatment has changed in the last twenty years since the discovery of EGFR mutations. In this article, we will review the current state of the art for non-small cell lung cancer actionable genomic alterations (AGA). AGA are mostly found in lung adenocarcinomas, a subtype of non-small cell lung cancers. We will focus on current treatment for EGFR mutations, ALK fusions, ROS1 fusions, BRAF V600E mutations, MET exon 14 skipping mutations, RET fusions, KRAS G12C mutations, ERBB2 mutations (also called HER2 mutations) and NTRK fusions. We will also touch on key toxicities associated with these medications. Treatments are mostly available for metastatic stage, but we will also discuss adjuvant therapy for EGFR mutations and ALK fusions as well as stage III post chemoradiotherapy treatment for EGFR lung cancer.
Keywords: 
lung cancer; molecular testing; targeted therapy
Subject: 
Medicine and Pharmacology  -   Oncology and Oncogenics
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Downloads

49

Views

45

Comments

0

Subscription

Notify me about updates to this article or when a peer-reviewed version is published.

Email

Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

Subscribe

© 2025 MDPI (Basel, Switzerland) unless otherwise stated